20-F: Nyxoah SA Files Form 20-F: Details Financial Performance and Corporate Governance

Nyxoah SA releases its annual report on Form 20-F, providing insights into its financial results, corporate governance, and future strategies.

Summary

• Nyxoah SA has released its annual report on Form 20-F, detailing the company's financial performance and corporate governance.
• The company's lead product is the Genio system, a CE-Marked neurostimulation therapy for obstructive sleep apnea.
• Nyxoah is currently conducting the DREAM pivotal trial to support marketing authorization in the United States.
• The company generated revenue of 4.3 million in 2023, compared to 3.1 million in 2022.
• Nyxoah experienced a net loss of 43.2 million in 2023.
• As of December 31, 2023, Nyxoah had cash and cash equivalents of 21.6 million and financial assets of 36.1 million.
• The company expects its operating expenses to continue to increase as it funds the development of its technology and expands its manufacturing and sales capabilities.
• There is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of the report without obtaining additional funding.
• The company identified material weaknesses in its internal control over financial reporting.
• Nyxoah is subject to various healthcare fraud and abuse laws and regulations.
• The company is also subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws.
• The company's success depends on its ability to protect its intellectual property and trade secrets.
• The dual listing of Nyxoah's ordinary shares may adversely affect the liquidity and value of the ordinary shares.
• The company is an emerging growth company and a foreign private issuer, which provides certain exemptions from U.S. securities laws.
• The company is subject to risks associated with international operations, including political and economic instability and currency fluctuations.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there is positive news regarding revenue growth and clinical trial progress, the significant net loss, material weaknesses in internal control, and going concern uncertainty weigh heavily on the overall outlook.

Positives

• Revenue increased to 4.3 million in 2023 from 3.1 million in 2022.
• The company is actively pursuing marketing authorization in the United States.
• The company is working to expand the indications for the Genio system.
• The company has a strong intellectual property portfolio.

Negatives

• Net loss was 43.2 million in 2023.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• Material weaknesses were identified in internal control over financial reporting.

Risks

• The company may not be able to achieve or maintain profitability.
• The company will require additional capital in the future, which may not be available on commercially favorable terms.
• The Genio system may not gain commercial acceptance in target markets.
• The company may not receive necessary marketing authorizations or certifications.
• The company is subject to extensive government regulation and oversight.
• The company's inability to fully protect and exploit its intellectual property and trade secrets may adversely affect its financial performance and prospects.
• The dual listing of the company's ordinary shares may adversely affect the liquidity and value of the ordinary shares.
• The company may be adversely affected by general political, unstable market and economic conditions and other events beyond its control.

Future Outlook

The company expects operating expenses to increase as it funds technology development, expands manufacturing and sales capabilities, seeks regulatory clearances, and incurs costs associated with being a public company.

Industry Context

The announcement highlights Nyxoah's position in the competitive medical technology industry, specifically in the market for obstructive sleep apnea treatments, where it faces competition from established players like Inspire Medical Systems and other emerging therapies.

Comparison to Industry Standards

• The document mentions Inspire Medical Systems, Inc., as a direct competitor with its Inspire Medical system, which is currently the only neurostimulation system approved to treat moderate to severe OSA in the United States.
• The Inspire Medical system's STAR trial demonstrated a 70% reduction in AHI from a baseline of 29.3 events per hour to 9.0 events per hour at 12 months following initial treatment and a 66% responder rate.
• Nyxoah's DREAM trial met its primary endpoints, with a 63.5% AHI responder rate and a 71.3% ODI responder rate, demonstrating comparable efficacy to existing neurostimulation therapies.

Related Party Transactions

• The company has entered into a consulting agreement with Olivier Taelman, the chief executive officer.
• The company has entered into an employment agreement with Loc Moreau, the chief financial officer.
• The company has entered into a collaboration agreement with Cochlear Limited.
• The company has entered into a multiparty agreement with Man & Science SA, Cephalix SA, Glucobel SA and Surgical Electronics SA regarding ownership and licensing rights.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional ordinary shares in future financings.
• The company's financial performance and ability to execute its strategy will impact its employees, customers, and suppliers.
• The company's ability to obtain regulatory approvals and reimbursement will impact patients' access to the Genio system.

Next Steps

• The company expects to apply for marketing authorization in the United States with the aim of being commercially available in the United States in late 2024.
• The company plans to continue to invest in research and development to improve the Genio system and develop new products.
• The company will continue to pursue and establish favorable reimbursement coverage of the Genio system.

Key Dates

Keywords

Nyxoah, Genio system, Obstructive Sleep Apnea, Financial Results, Corporate Governance, Form 20-F, DREAM Trial, Intellectual Property, Risk Factors, Financial Reporting